Mylan sued over alleged EpiPen exclusivity rebates

Nihal Krishan

25 April 2017

EpiPens (Credit: Greg Friese)

Sanofi sued EpiPen maker Mylan on Monday for allegedly suppressing competition in the market for drugs used to treat severe allergic reactions, by creating a rebate program for third party payors specifically conditioned on payors exclusively purchasing EpiPen.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Nihal Krishan

View full biography

Author

[email protected]

Tipline

Virtual reality check: The Tipline for 2 February 2023
The Federal Trade Commission’s challenge to Meta/Within was always going to be a soul-searching mission. Chair Lina Khan drew a line in the sand: the next Facebook/Instagram or Google/DoubleClick will not go by unchallenged. In the face of defeat, the Democratic majority must now decide whether to double down or save its scarce resources for another day. The agency did get somewhat of a boost elsewhere, however, with a pair of Senators introducing a …
Midnight blues: The Tipline for 1 February 2023
Fingers crossed: The Tipline for 31 January 2023